Valeant (VRX) Falls 5% as Financial Controls Questioned at Wells Fargo
Tweet Send to a Friend
Valeant Pharmaceuticals (NYSE: VRX) is down 5% Friday as Wells Fargo analyst David Maris highlighted that on September 7, 2017 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
